Geographic data shows that while production is global, the Human Insulin Market region of North America continues to lead in total revenue. This dominance is due to high healthcare expenditure and the early adoption of advanced analogs. However, Europe is quickly becoming a hub for biosimilar innovation, with several key approvals paving the way for lower-cost alternatives to high-priced brand-name insulins.

FAQ

• Which region is the fastest-growing? Asia-Pacific is expected to grow the fastest due to the rapid urbanization and lifestyle changes leading to higher diabetes rates.

• How does Europe lead in biosimilars? The European Medicines Agency (EMA) was one of the first to establish a clear regulatory pathway for approving "copy" versions of biologics.